CN102112124A - 保护正常细胞 - Google Patents

保护正常细胞 Download PDF

Info

Publication number
CN102112124A
CN102112124A CN2009801268109A CN200980126810A CN102112124A CN 102112124 A CN102112124 A CN 102112124A CN 2009801268109 A CN2009801268109 A CN 2009801268109A CN 200980126810 A CN200980126810 A CN 200980126810A CN 102112124 A CN102112124 A CN 102112124A
Authority
CN
China
Prior art keywords
sulindac
epimer
compositions
derivatives
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801268109A
Other languages
English (en)
Chinese (zh)
Inventor
赫伯特·魏斯巴赫
内森·布洛特
Original Assignee
Florida Atlantic University
New York Society for Relief of Ruptured and Crippled
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florida Atlantic University, New York Society for Relief of Ruptured and Crippled filed Critical Florida Atlantic University
Publication of CN102112124A publication Critical patent/CN102112124A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801268109A 2008-05-05 2009-05-04 保护正常细胞 Pending CN102112124A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/115,331 2008-05-05
US12/115,331 US8487128B2 (en) 2002-11-26 2008-05-05 Protection of normal cells
PCT/US2009/042703 WO2009137400A2 (en) 2008-05-05 2009-05-04 Protection of normal cells

Publications (1)

Publication Number Publication Date
CN102112124A true CN102112124A (zh) 2011-06-29

Family

ID=41265328

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801268109A Pending CN102112124A (zh) 2008-05-05 2009-05-04 保护正常细胞

Country Status (7)

Country Link
US (2) US8487128B2 (https=)
EP (1) EP2282733A4 (https=)
JP (1) JP2011520808A (https=)
CN (1) CN102112124A (https=)
AU (1) AU2009244500A1 (https=)
CA (1) CA2755499A1 (https=)
WO (1) WO2009137400A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740726A (zh) * 2017-05-04 2020-01-31 比亚韦斯托克高等医药大学 2-[(3z)-6-氟-2-甲基-3-[(4-甲基亚磺酰基苯基)亚甲基]茚-1-基]乙酸的新用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2882426A1 (en) * 2012-08-13 2015-06-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for treatment of cystic fibrosis
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
USRE48077E1 (en) 2013-02-28 2020-07-07 Anida Pharma Inc. Methods of treating ototoxicity
WO2014160702A1 (en) 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
JP6735225B2 (ja) * 2015-12-25 2020-08-05 共栄化学工業株式会社 皮膚外用組成物及び経口組成物
US11186534B2 (en) * 2017-03-17 2021-11-30 University Of South Alabama Derivatives of sulindac can protect normal cells against oxidative damage
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130575A3 (en) * 2006-05-03 2008-10-02 Univ Florida Atlantic Protection against oxidative damage in cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053429A (en) * 1988-04-08 1991-10-01 The Lithox Corporation, Inc. Treating inflammatory pain with methionine
US5401774A (en) * 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
US5608067A (en) * 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
EP1469884A1 (en) * 2002-01-30 2004-10-27 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
AU2003298020A1 (en) * 2002-11-26 2004-06-18 Florida Atlantic University Catalytic antioxidants and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130575A3 (en) * 2006-05-03 2008-10-02 Univ Florida Atlantic Protection against oxidative damage in cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740726A (zh) * 2017-05-04 2020-01-31 比亚韦斯托克高等医药大学 2-[(3z)-6-氟-2-甲基-3-[(4-甲基亚磺酰基苯基)亚甲基]茚-1-基]乙酸的新用途

Also Published As

Publication number Publication date
AU2009244500A1 (en) 2009-11-12
EP2282733A2 (en) 2011-02-16
US8871971B2 (en) 2014-10-28
EP2282733A4 (en) 2012-12-12
WO2009137400A2 (en) 2009-11-12
CA2755499A1 (en) 2009-11-12
US20140018429A1 (en) 2014-01-16
US20090326073A1 (en) 2009-12-31
JP2011520808A (ja) 2011-07-21
US8487128B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
CN102112124A (zh) 保护正常细胞
US20090069428A1 (en) Catalytic antioxidants and methods of use
US20210347735A1 (en) Deuterated compounds and uses thereof
TWI634888B (zh) 治療帕金森疾病的新穎高穿透性藥物和醫藥組合物
US5874468A (en) Brain targeted low molecular weight hydrophobic antioxidant compounds
JP2008538586A (ja) 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
WO2018039192A1 (en) Aldehyde trapping compounds and uses thereof
AU2017317529A1 (en) Aldehyde trapping compounds and methods of use thereof
US6420429B1 (en) Brain targeted low molecular weight hydrophobic antioxidant compounds
Pinnen et al. Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson’s disease
EP2010164A1 (en) S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
CN110996929A (zh) 使用硫醇化合物治疗神经系统疾病
Mani et al. Drug-induced oxidative stress and cellular toxicity
Guseva et al. Synthetic activators of autophagy
WO2007130575A2 (en) Protection against oxidative damage in cells
WO2007121545A1 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
US12071415B2 (en) Carbon monoxide prodrugs for the treatment of medical disorders
Mason et al. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids
US20230242558A1 (en) Nicotinate and nicotinamide riboside-based compounds and derivatives thereof
WO2017060400A1 (en) Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
JP2000510114A (ja) 抗酸化剤化合物
JP7699551B2 (ja) コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用
KR101325058B1 (ko) 신규한 케르세틴 유도체, 3',4'-디플루오로케르세틴, 그 제조방법 및 그 용도
CN102171185A (zh) 甲硫氨酸类似物及其使用方法
EP3532058B1 (en) Use of ciclopirox for the treatment of congenital erythropoietic porphyria

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CHS PHARMACY, INC

Free format text: FORMER OWNER: UNIV FLORIDA ATLANTIC

Effective date: 20131115

Free format text: FORMER OWNER: HOSPITAL FOR SPECIAL SURGERY

Effective date: 20131115

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20131115

Address after: American Florida

Applicant after: CHS pharmaceuticals Ltd

Address before: American Florida

Applicant before: Univ Florida Atlantic

Applicant before: Hospital For Special Surgery

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110629